| Literature DB >> 26419930 |
Ze-Bin Weng1, Qian-Qian Gao2, Fang Wang3, Gen-Hua Zhao2, Fang-Zhou Yin2, Bao-Chang Cai4, Zhi-Peng Chen5, Wei-Dong Li6.
Abstract
Estrogen replacement therapy (ERT) is utilized as a major regime for treatment of postmenopausal osteoporosis at present. However, long-term supplement of estrogen may cause uterine hyperplasia and hypertension leading to a high risk of endometrial cancer and breast cancer. Psoralea corylifolia L. has long been used as tonic and food additives in many countries. Previous studies had found two ingredients in P. corylifolia L.: bavachin and bakuchiol exhibited osteoblastic activity. The present study was designed to investigate the protective effect of bakuchiol and bavachin on ovariectomy-induced bone loss and explore the possible mechanism. In vivo, bakuchiol and bavachin could prevented estrogen deficiency-induced bone loss in ovariectomized rats without uterotrophic activity. In vitro studies suggested that bakuchiol and bavachin induced primary human osteoblast differentiation by up-regulating the Wnt signalling pathway. This study suggests that such a bone-protective role makes them a promising and safe estrogen supplement for the ERT.Entities:
Keywords: 17-β-estradiol (PubChem CID: 5757); Bakuchiol; Bakuchiol (PubChem CID: 5468522); Bavachin; Bavachin (PubChem CID: 5321775); Dimethyl sulfoxid (PubChem CID: 679); Methyl thiazolyl tetrazolium (PubChem CID: 16218671); Osteoblast; Postmenopausal osteoporosis; Wnt signalling pathway
Mesh:
Substances:
Year: 2015 PMID: 26419930 DOI: 10.1016/j.mce.2015.09.025
Source DB: PubMed Journal: Mol Cell Endocrinol ISSN: 0303-7207 Impact factor: 4.102